報價延遲最少15分鐘:2026/04/04 02:28 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.24 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.36/0.65
|
|
企業價值
201.98M
|
| 資產負債 |
|
每股賬面淨值
0.65
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
103.12M
|
|
每股收益
6.67
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. |
